Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Biogen to Buy Reata in $7.3 Billion Deal
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link
Hedge Funds Seek to Cut Off $1 Billion Meant for Opioid Victims
Drugmaker Mallinckrodt is talking to hedge funds about filing for bankruptcy and avoiding payments intended to help people addicted to opioids. Source link
U.K. Reviews Safety of Ozempic, Other Weight-Loss Drugs
Drug regulators said they have received several reports of suspected suicidal and self-injurious behavior in patients taking the drugs. Source link
Biogen to Cut Roughly 11% of Workforce
The biotech cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products. Source link
How U.S. Drug Companies Could Tip Europe Into Recession
Swings in Ireland’s pharmaceutical industry, often rooted in tax moves by U.S.-based firms, have outsize impact on European output. Source link
Big Pharma Bets Big on China
China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. Source link
J&J Revenue Up on Surge in Heart Procedures
Net earnings at the pharmaceutical company rose 6.9% to $5.14 billion, or $1.96 a share. Source link
Tornado Damages Key Pfizer Drugmaking Plant
The plant in Rocky Mount, N.C., produces a quarter of the sterile injectable medicines used by U.S. hospitals. Source link
Elliott Takes Big Stake in Drugmaker Catalent
The activist is pushing for a shake-up of the contract drug manufacturer’s board. Source link
Johnson & Johnson Rips Off the Kenvue Band-Aid
A surprisingly early distribution and a stretched valuation hit J&J’s consumer health arm hard. Source link